The activity of L-type Ca 2؉ channels is increased by dihydropyridine (DHP) agonists and inhibited by DHP antagonists, which are widely used in the therapy of cardiovascular disease. These drugs bind to the pore-forming ␣ 1 subunits of L-type Ca 2؉ channels. To define the minimal requirements for DHP binding and action, we constructed a high-affinity DHP receptor site by substituting a total of nine amino acid residues from DHP-sensitive L channel blockers that are widely used in the therapy of cardiovascular diseases; DHP modulation is the hallmark used to characterize these channels (reviewed in refs. 3 and 4) .
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The L-type Ca 2ϩ channels consist of pore-forming ␣ 1 subunits of 190 to 250 kDa in association with disulfide-linked ␣ 2 ␦ subunits of approximately 140 kDa, intracellular ␤ subunits of 55 to 72 kDa, and, for the skeletal muscle L-type channel, an additional transmembrane ␥ subunit of 33 kDa (5). The ␣ 1 subunits confer the characteristic pharmacologic and functional properties of Ca 2ϩ channels, but their function is modulated by association with the auxiliary subunits. The pore-forming ␣ 1 subunits can be divided into two distinct families, L-type and non-L-type, that share less than 40% amino acid identity. The L-type ␣ 1 subunit family includes ␣ 1S , which is expressed in skeletal muscle (6) , ␣ 1C , which is expressed in cardiac and smooth muscle, neurons, and many other cell types (7) (8) (9) , and ␣ 1D , which is expressed in endocrine and neuronal cells (10, 11) . The non-L-type ␣ 1 subunit family consists of at least three distinct gene products that are expressed primarily in neurons: ␣ 1B (N-type; refs. 12 and 13), ␣ 1A (P͞Q-type; refs. 14 and 15), and ␣ 1E (R-type; ref. 16 ). The ␣ 1 subunits contain four homologous domains (I through IV) that each contain six transmembrane segments (S1 through S6) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) channel subtypes had large effects on DHP affinity (35, 36) . In addition, mutations of residues that differ between L-type and non-L-type Ca 2ϩ channels revealed multiple amino acids in transmembrane segments IIIS5, IIIS6, and IVS6 that are important determinants of high-affinity binding of DHP agonists and antagonists to L-type Ca 2ϩ channels (34) (35) (36) (37) (38) . In the experiments reported here, we have substituted nine key amino acid residues that are present in all L-type ␣ 1 subunits into the non-L-type ␣ 1A subunit and measured both activation by DHP agonists and inhibition by DHP antagonists. The results show that these nine amino acid residues are sufficient to constitute a highaffinity receptor site for DHPs that responds appropriately to both DHP agonists and antagonists and is stereoselective like the native DHP receptor of L-type Ca 2ϩ channels.
EXPERIMENTAL PROCEDURES

Construction of Mutant Ca
2؉ Channels. For the construction of ␣ 1A/DHPS , the AscI-BsrGI fragment (nucleotides 2582-5408) from ␣ 1A (14) was ligated into pNEB193 (New England Biolabs) and used as template for mutagenic PCR reactions. The mutations in transmembrane segment IIIS5 were made in a single PCR reaction using primers that overlapped the BstXI (nucleotide 2950) and ApoI (nucleotide 4057) sites. The mutagenic mismatches were incorporated by the primer overlapping the ApoI site. The mutations in IIIS6 were made in a single PCR reaction using primers that overlapped the XcmI (nucleotide 4316) and BspEI (nucleotide 5102) sites. The mutagenic mismatches were incorporated by the primer overlapping the XcmI site. The mutations in IVS6 were made using the splice overlap extension method (39) . In the first reactions, mutagenic primers annealing within the cDNA encoding IVS6 were paired with primers that overlapped either the BspEI or the NotI (nucleotides 5102 and 5384, respectively) sites that flank IVS6. These overlapping fragments were coupled and amplified in a subsequent PCR reaction to give the full-length BspEI-NotI fragment containing the mutations in IVS6. The PCR products containing the desired mutations were assembled in AscI-BsrGI͞pNEB193, and the AscI-BsrGI fragment was ligated into full-length ␣ 1A in the expression vector pMT2. The desired mutations were verified, and the integrity of the clone was confirmed by cDNA sequencing and extensive restriction digest analysis.
Expression of Ca 2؉ Channels. Human tsA-201 cells, a simian virus 40 (SV40) T-antigen expressing derivative of the human embryonic kidney cell line HEK293 (a gift of Robert DuBridge, Cell Genesis, Foster City, CA), were maintained in DMEM͞F-12 (GIBCO͞BRL) enriched with 10% fetal bovine serum. Human tsA-201 cells were cotransfected with ␣ 1A , ␣ 1A/DHPS , or ␣ 1CII (9); ␤ 1b (40) ; ␣ 2 ␦ (41); and CD8 antigen (EBO-pCD-Leu2, American Type Culture Collection) such that the molar ratio of the plasmids was 1:1:1:0.8. Cells were transfected by Ca 2ϩ phosphate precipitation (42) , and cells were replated at low density for electrophysiological recording 20-24 hours later. The ␣ 1CII cDNA was in the expression plasmid ZEM 229 (a gift of Eileen Mulvihill, Zymogenetics, Seattle). The ␣ 2 ␦ cDNA was in the expression plasmid ZEM 228 (a gift of Eileen Mulvihill). The ␣ 1A , ␣ 1A/DHPS , and ␤ 1b cDNA were in the expression plasmid pMT2 (Genetics Institute, Boston).
Electrophysiology. Transfectants were recognized by labeling with anti-CD8 antibody-coated beads (M450 CD8 Dynabeads, Dynal). Barium currents through Ca 2ϩ channels were recorded using the whole-cell configuration of the patch clamp technique. Patch electrodes were pulled from VWR micropipettes and fire-polished to produce an inner tip diameter of 4-6 m. Currents were recorded using an Axon Instruments Axopatch 200B patch clamp amplifier and filtered at 1 or 2 kHz (8-pole Bessel filter, Ϫ3 dB). Voltage pulses were applied and data were acquired using pClamp6 software (Axon Instruments). Linear leak and capacitance currents have been subtracted using an on-line P͞Ϫ4 subtraction paradigm. (Ϯ)PN200-110 was applied to cells using a fast perfusion system with background perfusion. (Ϫ)Bay K 8644 was added to the bath, without background perfusion, as a 10ϫ stock. The bath saline contained 150 mM of Tris, 2 mM of MgCl 2 , and 10 mM of BaCl 2 . The intracellular saline contained 130 mM of N-methyL-D-glucamine, 10 mM of EGTA, 60 mM of Hepes, 2 mM of MgATP, and 1 mM of MgCl 2 . The pH of both solutions was adjusted to 7.3 with methanesulfonic acid. All experiments were performed at room temperature (20-23°C).
Preparation of Membranes. Transfected tsA-201 cells were washed twice, scraped from the cell culture dish, and homogenized using a glass-teflon homogenizer in Buffer A (50 mM of Tris͞100 M of phenylmethylsulfonyl fluoride͞100 M of benzamidine͞1.0 M of pepstatin A͞1.0 g/ml of leupeptin͞ 2.0 g/ml of aprotinin, pH 8.0). The homogenate was centrifuged at 700 ϫ g for 5 min. The resulting pellet was discarded and the supernatant was centrifuged 30 min at 100,000 ϫ g. The supernatant was discarded and the membrane pellet was washed and homogenized in Buffer A. The resulting membrane homogenate was divided into aliquots and stored at Ϫ80°C for up to 3 months with no detectable loss of (ϩ)- at 32°C for 180-210 min. Nonspecific binding was determined in the presence of 1 M (Ϯ)-PN200-110, and bound and free ligands were separated by vacuum filtration over GF͞C glass fiber filters. Filters were washed using ice-cold wash buffer (10 mM of Tris͞1% polyethylene glycol 8000͞0.1% BSA͞0.01% Triton X-100, pH 8.0), and bound radioactivity was detected by liquid scintillation counting. Dissociation constants (K D ) were determined using the radioligand data analysis program LIGAND (Biosoft, Cambridge, U.K.). All data are means Ϯ SEM.
RESULTS
Construction of a High Affinity DHP Site in ␣ 1A . The key amino acid residues required for high affinity DHP binding as determined in previous studies are illustrated in Fig. 1 . Photoaffinity labeling followed by antibody mapping of the labeled peptide fragments showed that transmembrane segments IIIS6 and IVS6 are components of the DHP receptor site in L-type Ca 2ϩ channels (refs. 28 and 29; Fig. 1 A, shaded segments) . Construction and analysis of chimeric Ca 2ϩ channels confirmed the importance of transmembrane segments IIIS6 (32) and IVS6 (32) (33) (34) Studies of single amino acid substitutions in L-type channels revealed nine L-type-specific (black circles with white letters) and five conserved (white circles with black lower case letters) amino acid residues to be critical for DHP binding and block of L-type channels (34) (35) (36) (37) (38) . The nine L-type-specific amino acid residues critical for DHP action were inserted into the DHP-insensitive ␣1A subunit amino acid sequence (14) (white circles with black letters) to a construct a mutant ␣1A subunit that is modulated by DHPs (␣1A/DHPS). channels are transferred into non-Ltype Ca 2ϩ channels suggests that the basic structure of non-L-type channels is appropriate to support DHP binding, even though the amino acid sequence is less than 40% identical. Similarly, the requirement for amino acid residues that are conserved between L-type and non-L-type Ca 2ϩ channels for high-affinity DHP binding suggests that the DHP binding site contains structural features that are common to all Ca 2ϩ channels. If all of the L-type-specific amino acid residues that are required for high affinity DHP binding have been identified, substitution of the nine amino acid residues highlighted as dark circles in Fig. 1B into a non-L-type Ca 2ϩ channel should be sufficient to construct a high-affinity DHP binding site. To test this idea, we substituted these nine amino acid residues for their counterparts in the DHP-insensitive rbA isoform of the ␣ 1A subunit of P͞Q-type Ca 2ϩ channels using site-directed mutagenesis methods as described in Experimental Procedures.
Functional Characteristics of the DHP-Sensitive ␣ 1A Chimera. The resulting ␣ 1A/DHPS subunit was expressed in tsA-201 cells with ␣2␦ and ␤1b subunits and analyzed by whole cell voltage clamp as described in Experimental Procedures. Barium currents through the ␣ 1A/DHPS subunit activated normally but inactivated more rapidly than wild-type ␣ 1A ( Fig. 2A ; ␣ 1A , h ϭ 279 ms; ␣ 1A/DHPS , h ϭ 123 ms). The two channels had similar current-voltage relationships with peak barium current near 0 mV (Fig. 2B) . However, the voltage dependence of inactivation of ␣ 1A/DHPS was shifted 40 mV toward more negative membrane potentials compared with wild-type ␣ 1A ( Fig. 2C ; ␣ 1A , V h1/2 ϭ Ϫ48 mV; ␣ 1A/DHPS , V h1/2 ϭ Ϫ88 mV). Thus, the ␣ 1A/DHPS chimera is functional as a Ca 2ϩ channel, but has altered inactivation properties.
Inhibition of Barium Currents Through ␣ 1A/DHPS by a DHP Antagonist. DHP antagonists bind with higher affinity to the inactivated state of L-type Ca 2ϩ channels (43) (44) (45) . To compare the DHP sensitivity of wild-type ␣ 1A and ␣ 1A/DHPS , we compensated for the shift in the voltage dependence of inactivation by measuring the block of barium currents from holding potentials that differed by 40 mV: Ϫ80 mV for ␣ 1A and Ϫ120 mV for ␣ 1A/DHPS . These conditions yield the same ratio of resting and inactivated channels for each ␣ 1 subunit. The more negative membrane potential used for the ␣ 1A/DHPS chimera would reduce inhibition of L-type Ca 2ϩ channels by DHPs, so it is unlikely that this membrane potential per se would increase inhibition of the ␣ 1A/DHPS chimera.
The high-affinity DHP antagonist PN200-110 (isradipine) had no effect on P͞Q-type Ca 2ϩ channels containing ␣ 1A , even at the high concentration of 10 M (Fig. 3A) . In contrast, chimeric Ca 2ϩ channels containing ␣ 1A/DHPS were substantially inhibited by 10 nM of PN200-110 and completely inhibited by 100 nM of PN200-110 (Fig. 3A) . The IC 50 value estimated from titration experiments was 13.8 nM Ϯ 3 nM (Fig. 3C, n ϭ  9 ). This compares favorably with the IC 50 of 6.8 nM Ϯ 1 nM for block of L-type Ca 2ϩ channels containing ␣ 1C expressed with ␣2␦ and ␤1b in the same cell line (Fig. 3B) . Ca 2ϩ channels containing ␣ 1A are unaffected by PN200-110 up to at least 10 M. Based on this, the minimum estimate of the IC 50 for inhibition of P͞Q-type Ca 2ϩ channels containing ␣ 1A is 250 M, more than four orders of magnitude higher than for ␣ 1A/DHPS . Thus, substitution of nine amino acid residues in ␣ 1A is sufficient to constitute a high affinity receptor site for a DHP antagonist with more than 10,000-fold higher affinity than wild-type ␣ 1A .
Increase of Barium Currents Through ␣ 1A/DHPS by a DHP Agonist. DHPs are allosteric modulators of L-type Ca 2ϩ channels and can either inhibit or enhance channel activity (3, 4, 17) . Activation of L-type Ca 2ϩ channels is increased by DHP agonists like (Ϫ)Bay K8644 (17) . Our previous results on mutations in the ␣ 1S subunit of L-type Ca 2ϩ channels indicated that many of the same amino acid residues are required for binding of both DHP agonists and antagonists (35) . To test whether DHP agonists can also bind and act at the minimal DHP receptor site constructed in ␣ 1A/DHPS , we measured barium currents from a holding potential of Ϫ100 mV in the presence and absence of 10 M (Ϫ) Bay K8644 (Fig. 4) . Bay K8644 increased Ca 2ϩ currents through L-type Ca 2ϩ channels containing ␣ 1C , but had no effect on P͞Q-type channels containing ␣ 1A (Fig. 4 Left) . In contrast, (Ϫ) Bay K8644 increased barium currents through chimeric Ca 2ϩ channels containing ␣ 1A/DHPS by 3.53 Ϯ 0.66-fold (Fig. 4 Left; n ϭ 3) . The increased barium current was observed over a wide range of test pulse potentials, as for L-type Ca 2ϩ channels containing ␣ 1C (Fig. 4 Right) . In contrast, (Ϫ) Bay K8644 had no effect on barium currents through P͞Q-type Ca 2ϩ channels containing ␣ 1A at any test pulse potential (Fig. 4 Right) . Thus, the minimal DHP receptor site of ␣ 1A/DHPS is sufficient for both binding and functional effect of a DHP agonist. (open circles) and ␣1A/DHPS (solid circles). Cells expressing ␣1A or ␣1A/DHPS were held at Ϫ80 mV or Ϫ120 mV, respectively. From these holding potentials, cells were depolarized to the indicated conditioning pulse potentials for 10 seconds, followed immediately by a 100 ms test pulse to 0 mV. The amplitude of the Ca 2ϩ current during the test pulse is plotted against the voltage of the preceding 10 s conditioning pulse. Smooth lines are fits to a Boltzman function with slope factors of 12.7 and 17.3 for ␣1A and ␣1A/DHPS, respectively. For ␣1A, Vh1/2 ϭ Ϫ47.7 Ϯ 1.8 mV (n ϭ 6), and for ␣1A/DHPs, Vh1/2 ϭ Ϫ88.1 Ϯ 1.0 mV (n ϭ 4). The functional effects of many DHP agonists are stereospecific. For Bay K8644, the (Ϫ) enantiomer is an agonist while the (ϩ) isomer is an antagonist (17) . As for L-type Ca 2ϩ channels containing ␣ 1C , we found that chimeric Ca 2ϩ channels containing ␣ 1A/DHPS are inhibited by (ϩ) Bay K8644 (IC 50 ϭ 303 Ϯ 102 nM, n ϭ 8; data not shown), and no activating effect of (ϩ) Bay K8644 was observed at any concentration tested. Thus, the stereoselectivity of DHP binding and action is also present in the minimal DHP receptor site constructed in ␣ 1A/DHPS .
High Affinity Binding of PN200-110 to ␣ 1A/DHPS in Cell Membrane Preparations. Inhibition of barium currents by PN200-110 measures primarily drug binding to the resting state of Ca 2ϩ channels that is predominant at the negative holding potential. Because DHP antagonists have higher affinity for the inactivated state of Ca 2ϩ channels (43) (44) (45) , their binding affinity is higher in radioligand binding assays using membrane preparations whose membrane potential is near 0 mV where inactivation is complete. We first compared binding of To compare the binding affinity of ␣ 1C and ␣ 1A/DHPS quantitatively, we carried out a saturation binding study (Fig. 5A ) and analyzed the data by Scatchard plot (Fig. 5B , note the different axes for ␣ 1C and ␣ 1A/DHPS ). The results indicate a K D for binding to ␣ 1C of 50 pM compared with a K D for ␣ 1A/DHPS of 1.48 nM, 27-fold higher. Thus, the ␣ 1A/DHPS chimera has high affinity for PN200-110 in a radioligand binding assay as well as in electrophysiological experiments, but the difference in binding between ␣ 1C and ␣ 1A/DHPS is greater in the ligand binding assay.
DISCUSSION
Molecular Requirements for a High Affinity DHP Receptor Site. Substitution of nine amino acid residues previously shown to be required for DHP binding (34) (35) (36) (37) (38) into the sequence of the non-L-type ␣ 1A subunit is sufficient to construct a highaffinity DHP receptor site. This site was constructed in the structural context of the ␣ 1A subunit that contains at least five conserved residues that are necessary for high-affinity DHP binding (35, 36) . The resulting chimera ␣ 1A/DHPS has many of the pharmacological properties of an L-type Ca . Cells expressing ␣1A, or ␣1A/DHPS were depolarized from a holding potential of Ϫ100 mV to 0 mV for 100 ms. Cells expressing ␣1C were held at Ϫ60 mV and depolarized to ϩ10 mV for 100 ms. For Ca 2ϩ channels containing ␣1A or ␣ 1A/DHPS, a series of ten 1 s depolarizations to 0 mV was used to bring the agonist effect to equilibrium. (Right) Current-voltage relationship before and after addition of 10 M of (Ϫ) Bay K 8644 is shown for each channel type. The peak current amplitude of each I/V curve in the absence of (Ϫ) Bay K 8644 was set to 1, and the current amplitudes in the presence of (Ϫ) Bay K 8644 were expressed relative to the current amplitudes in the absence of drug. Cells expressing ␣1A or ␣1A/DHPS were held at Ϫ80 mV or Ϫ120 mV, respectively. From these holding potentials, cells were depolarized to the indicated test pulse potentials from Ϫ50 mV to ϩ50 mV in 10 mV increments for 100 ms, and barium currents were recorded. may be contributed by several amino acid residues whose mutation had measurable, but less than twofold, effects on DHP binding affinity (35, 36) or by the overall structural context of ␣ 1A versus ␣ 1C and ␣ 1S .
A Single Receptor Site for DHP Agonists and Antagonists. DHP agonists inhibit high-affinity binding of DHP antagonists, consistent with the idea that they share the same receptor site (45) (46) (47) . However, binding studies on intact cells reveal complex interactions between binding of agonist and antagonist DHPs, and it has been hypothesized that agonists and antagonists occupy different sites when causing their opposite effects on Ca 2ϩ channel function (48) . In contrast to this hypothesis, our results show conclusively that DHP agonists and antagonists occupy the same receptor site and cause opposite effects on Ca 2ϩ channel activity when bound there. Each of the nine single amino acids substituted in ␣ 1A/DHPS is required for high-affinity antagonist binding in L-type Ca 2ϩ channels, and mutations of many of these residues also reduce affinity for binding of agonists to L-type channels. Construction of a minimal DHP receptor site for high-affinity antagonist binding also is sufficient to confer stereoselective agonist binding and action. Molecular differences in the interactions of these two classes of drugs with the same receptor site must be responsible for the dramatic differences in their pharmacological effects.
A Domain-Interface Model for DHP Binding and Action. Based on the original photoaffinity labeling of the DHP receptor site, it was proposed that DHPs bind to a single site at the interface of domains III and IV (30) . This model is confirmed by the results presented here, which show that the minimal receptor site sufficient for high-affinity binding of DHP antagonists and for stereoselective binding and action of DHP agonists includes amino acid residues in transmembrane segments S5 and S6 in domain III and transmembrane S6 in domain IV. Allosteric effectors of enzymes most often bind to sites at the interfaces between subunits or domains (e.g., refs. 49 and 50), and current evidence indicates that the agonist binding site of nicotinic acetylcholine receptors is at a subunit interface (51) . Evidently, these sites are particularly sensitive to binding of small ligands, which can alter interactions between domains or subunits when bound at their interface. Based on these analogies, it is likely that DHPs act as allosteric effectors that alter domain-domain interactions within the ␣ 1 subunits of Ca 2ϩ channels. Determination of the structural basis for the opposite, stereoselective effects of DHP agonists and antagonists on Ca 2ϩ channel function when bound at the DHP receptor site between domains III and IV will provide further information on the mechanism of action of these drugs and on the interactions between these Ca 2ϩ channel domains in channel gating.
